Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations.

Abstract:

:Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.

authors

Altman RD

doi

10.1586/ecp.09.17

subject

Has Abstract

pub_date

2009-07-01 00:00:00

pages

359-71

issue

4

eissn

1751-2433

issn

1751-2441

journal_volume

2

pub_type

杂志文章
  • Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.

    abstract:INTRODUCTION:Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1540299

    authors: Angeli F,Trapasso M,Signorotti S,Verdecchia P,Reboldi G

    更新日期:2018-11-01 00:00:00

  • Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

    abstract::Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1100072

    authors: Ali KF,Shukla AP,Aronne LJ

    更新日期:2016-01-01 00:00:00

  • A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

    abstract::Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1552134

    authors: Esposito A,Viale G,Criscitiello C,Curigliano G

    更新日期:2019-01-01 00:00:00

  • Antioxidants in the prevention of myocardial ischemia/reperfusion injury.

    abstract::In acute myocardial ischemia (AMI) the optimal treatment is rapid revascularization by angioplasty or pharmacological thrombolysis. While this is essential to resuscitate the ischemic myocardium, it results in further reperfusion injury and extension of the infarction. The main hypothesis for the mechanism of reperfus...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.41

    authors: Qin C,Yap S,Woodman OL

    更新日期:2009-11-01 00:00:00

  • Effects of red wine on established markers of arterial structure and function in human studies: current knowledge and future research directions.

    abstract::Evidence from observational studies suggests that mild-to-moderate consumption of red wine is associated with reduced cardiovascular morbidity and mortality. Various individual chemical components of red wine also show salutary effects on vascular homeostasis, that is, enhanced endothelial function and arterial disten...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2013.841077

    authors: Mangoni AA,Stockley CS,Woodman RJ

    更新日期:2013-11-01 00:00:00

  • Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.

    abstract::In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device. Long-acting muscarinic antagonists such as glycop...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.828419

    authors: Molimard M,D'Andrea P

    更新日期:2013-09-01 00:00:00

  • The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field.

    abstract::Introduction: The placenta is a temporary and unique organ that allows for the physical connection between a mother and fetus; this organ regulates the transport of gases and nutrients mediating the elimination of waste products contained in the fetal circulation. The placenta performs metabolic and excretion function...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1733412

    authors: Blanco-Castañeda R,Galaviz-Hernández C,Souto PCS,Lima VV,Giachini FR,Escudero C,Damiano AE,Barragán-Zúñiga LJ,Martínez-Aguilar G,Sosa-Macías M

    更新日期:2020-03-01 00:00:00

  • Secukinumab (AIN-457) for the treatment of Psoriasis.

    abstract::Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1129894

    authors: Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

    更新日期:2016-01-01 00:00:00

  • Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

    abstract::Introduction: Dementia is the 7th leading cause of death that imposes a significant financial and service burden on the global population. Presently, only symptomatic care exists for cognitive loss, such as Alzheimer's disease.Areas covered: Given the advancing age of the global population, it becomes imperative to de...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1698288

    authors: Maiese K

    更新日期:2020-01-01 00:00:00

  • Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.

    abstract:INTRODUCTION:Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1774362

    authors: Carena AA,Stryjewski ME

    更新日期:2020-06-01 00:00:00

  • Statin intolerance: more questions than answers.

    abstract::The dramatic effectiveness of statins in improving the course of atherosclerotic cardiovascular disease tends to overshadow questions of statin intolerance. Thus after more than 25 years of clinical statin use, intolerance remains a poorly understood, frustrating issue for patients and providers. It has been extraordi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2014.857601

    authors: Guyton JR,Campbell KB,Lakey WC

    更新日期:2014-01-01 00:00:00

  • Novel Therapies for Thyroid Autoimmune Diseases.

    abstract::C-X-C chemokine receptor (CXCR)3 and its interferon(IFN)γ-dependent chemokines (CXCL10, CXCL9, CXCL11) are implicated in the immune-pathogenesis of autoimmune thyroiditis (AT), Graves disease (GD) and Graves Ophthalmopathy (GO). In tissue, recruited Th1 lymphocytes produce IFNγ, enhancing the tissue secretion of IFNγ-...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1157468

    authors: Fallahi P,Ferrari SM,Elia G,Nasini F,Colaci M,Giuggioli D,Vita R,Benvenga S,Ferri C,Antonelli A

    更新日期:2016-06-01 00:00:00

  • Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.

    abstract:INTRODUCTION:A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1341308

    authors: Nelson AL

    更新日期:2017-08-01 00:00:00

  • Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.

    abstract::Oncology is one of the areas of medicine with the most active research being conducted on new drugs. New pharmacological entities frequently enter the clinical arena, and therefore, the safety profile of anticancer products deserves continuous monitoring. However, only very severe and (unusual) suspected adverse drug ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.974555

    authors: Tuccori M,Montagnani S,Capogrosso-Sansone A,Mantarro S,Antonioli L,Fornai M,Blandizzi C

    更新日期:2015-01-01 00:00:00

  • Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.

    abstract:INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1333902

    authors: Watanabe Y,Tatsuno I

    更新日期:2017-08-01 00:00:00

  • Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.

    abstract::The anti-tumor activity of CpG-containing oligodeoxynucleotides (ODNs) has been well established in numerous animal models and confirmed in a number of early clinical trials. While the use of chemical modifications has effectively reduced the sensitivity of ODNs to nuclease degradation and a number of human trials hav...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2.2.181

    authors: Wilson KD,Tam YK

    更新日期:2009-03-01 00:00:00

  • Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.

    abstract::Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.945910

    authors: Tong LX,Moore AY

    更新日期:2014-09-01 00:00:00

  • Pharmacological management of diabetic dyslipidemia.

    abstract:INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1263565

    authors: Filippatos TD,Florentin M,Georgoula M,Elisaf MS

    更新日期:2017-02-01 00:00:00

  • Pharmacological treatment of pediatric Gaucher disease.

    abstract:INTRODUCTION:Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical ou...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1549486

    authors: Gupta P,Pastores G

    更新日期:2018-12-01 00:00:00

  • Strategies for recombinant production of antimicrobial peptides with pharmacological potential.

    abstract:INTRODUCTION:The need to develop new drugs for the control of pathogenic microorganisms has redoubled efforts to prospect for antimicrobial peptides (AMPs) from natural sources and to characterize its structure and function. These molecules present a broad spectrum of action against different microorganisms and frequen...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1764347

    authors: Sampaio de Oliveira KB,Leite ML,Rodrigues GR,Duque HM,da Costa RA,Cunha VA,de Loiola Costa LS,da Cunha NB,Franco OL,Dias SC

    更新日期:2020-04-01 00:00:00

  • G-quadruplex interacting small molecules and drugs: from bench toward bedside.

    abstract::G-quadruplexes are non-Watson-Crick four-stranded nucleic acid structures. Recent evidence points toward their existence in vivo and their implication in various biological processes. Over the past two decades, small molecules have been developed to specifically and selectively target these structures in order to diss...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.945909

    authors: Müller S,Rodriguez R

    更新日期:2014-09-01 00:00:00

  • Atezolizumab for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1356717

    authors: Santini FC,Rudin CM

    更新日期:2017-09-01 00:00:00

  • Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

    abstract::Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-up data. Methods: The phase II RESORT trial randomized patients to sorafenib or observation within 12 weeks from surgery. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2021.1879639

    authors: Mennitto A,Verzoni E,Cognetti F,Miceli R,Milella M,Mosca A,Chiuri VE,Bearz A,Morelli F,Ortega C,Atzori F,Donini M,Claps M,Guadalupi V,Sepe P,Cappelletti V,de Braud FG,Procopio G

    更新日期:2021-01-31 00:00:00

  • Lucinactant for the prevention of respiratory distress syndrome in premature infants.

    abstract::Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.80

    authors: Jordan BK,Donn SM

    更新日期:2013-03-01 00:00:00

  • Antiepileptic drugs influences on body weight in people with epilepsy.

    abstract::Data from clinical trials, retrospective and cross-sectional studies have quantified the metabolic changes associated with long-term use of antiepileptic drugs (AEDs). AEDs can be associated with weight gain or weight loss, although most are weight neutral. Weight gain is not only a cosmetic problem but also a risk fo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.991716

    authors: Hamed SA

    更新日期:2015-01-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1665026

    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • Combating inappropriate use of medicines.

    abstract::Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of resources and causes patient harm in terms of lack of satisfactory outcome, serious ad...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.14

    authors: Holloway KA

    更新日期:2011-05-01 00:00:00

  • Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.

    abstract:INTRODUCTION:The incidence of kidney dysfunction increases with age and is highly prevalent among patients with hypertension. Since many therapeutic compounds are primarily eliminated through the kidneys, impaired renal function can have negative consequences on drug disposition, efficacy and safety. Therefore, regulat...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1274651

    authors: Paglialunga S,Offman E,Ichhpurani N,Marbury TC,Morimoto BH

    更新日期:2017-03-01 00:00:00

  • Novel pharmaceuticals in the management of postoperative pain.

    abstract::Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2015.1072465

    authors: Palmer P

    更新日期:2015-01-01 00:00:00

  • Pharmacodynamics of TNF-α inhibitors in psoriasis.

    abstract::Over the last two decades, research developments have revolutionized our understanding of the pathogenesis of psoriasis and of the contribution of several cytokines in the manifestation of the disease. The key role of TNF-α in the pathogenesis of psoriasis has been extensively studied and its therapeutic action, initi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.28

    authors: Vergou T,Moustou AE,Sfikakis PP,Antoniou C,Stratigos AJ

    更新日期:2011-07-01 00:00:00